BENZIMIDAZOLE SCAFFOLD: A PRIVILEGED CORE FOR DIVERSE PHARMACOLOGICAL ACTIVITIES
Abstract
Microbes have a substantial role in the spread of dangerous infections, and how they spread to humans presents an increasing challenge to public health. The effective management of these types of infections and the mitigation of antimicrobial resistance can be accomplished using novel pharmaceuticals, which are essential to ongoing research within the scientific community. The strategic use of current antimicrobial alternatives alongside novel drug regimens warrants investigation to address the significant issue of drug resistance. Extended research in antimicrobial drugs has shown that, among various targets, targeting proteins is the most effective approach for developing robust treatments. Despite considerable progress in antibiotic therapies and the availability of various inhibitors for drug-resistant bacterial strains, there remains a critical necessity to develop new compounds that possess a favourable safety profile to tackle this issue. In immunocompromised individuals, severe diseases resulting from pathogenic fungi are frequently observed. Fungal infections are common, yet treatment options remain limited; thus, the development of new antifungal agents is crucial for community members.
Keywords:
Benzimidazole, Pharmacological activity, Bioactive scaffold, Drug design, Therapeutic agents, Heterocyclic compounds
References
1. Bazine I, Bendjedid S, Boukhari A. Potential antibacterial and antifungal activities of novel sulfamidophosphonate derivatives bearing the quinoline or quinolone moiety. Arch Pharm (Weinheim). 2021; 354(2): 2000426.
2. Shinde RA, Adole VA, Jagdale BS, Pawar TB. Superfast synthesis, antibacterial and antifungal studies of halo-aryl and heterocyclic tagged 2,3-dihydro-1H-inden-1-one candidates. Monatsh Chem. 2021; 152: 649–658.
3. Reddy GM, Kumari AK, Reddy VH, Garcia JR. Novel pyranopyrazole derivatives comprising a benzoxazole core as antimicrobial inhibitors: Design, synthesis, microbial resistance and machine-aided results. Bioorg Chem. 2020; 100: 103914.
4. Odusami JA, Ikhile MI, Izunobi JU. Synthesis of substituted N-(2′-nitrophenyl)pyrrolidine-2-carboxamides towards the design of proline-rich antimicrobial peptide mimics to eliminate bacterial resistance to antibiotics. Bioorg Chem. 2020; 105: 104408.
5. El Faydy M, Dahaieh N, Ounine K. Synthesis, identification, antibacterial activity, ADME/T and 1BNA-docking investigations of 8-quinolinol analogs bearing a benzimidazole moiety. Arab J Sci Eng. 2022; 47: 497–510.
6. Di Luca M, Marzo T. Development of effective antibacterial treatment: Lessons from the past and novel approaches. Antibiotics (Basel). 2021; 10(2): 230.
7. Mohanty P, Behera S, Behura R. Antibacterial activity of thiazole and its derivatives: A review. Biointerface Res Appl Chem. 2022; 12: 2171–2195.
8. Rivera JA, Larsson J, Volkov IL. Real-time measurements of aminoglycoside effects on protein synthesis in live cells. Proc Natl Acad Sci U S A. 2021; 118(2): e2013315118.
9. Almeida L, Dhillon-LaBrooy A, Castro CN. Ribosome-targeting antibiotics impair T cell effector function and ameliorate autoimmunity by blocking mitochondrial protein synthesis. Immunity. 2021; 54(1): 68–83.
10. Darwis W, Supriati R, Sipriyadi. Antibacterial potency of lichen Teloschisthes flavicans from Kepahiang district against Staphylococcus aureus and Pseudomonas aeruginosa. Proc 3rd KOBI Congr Int Natl Conf (KOBICINC 2020). 2021; 14: 547–552.
11. Wei MP, Yu H, Guo YH. Synergistic antibacterial combination of sapindoside A and B changes the fatty acid compositions and membrane properties of Cutibacterium acnes. Microbiol Res. 2021; 255: 126888.
12. Sonousi A, Quirke JCK, Waduge P. An advanced apralog with increased in vitro and in vivo activity toward gram-negative pathogens and reduced ex vivo cochleotoxicity. ChemMedChem. 2021; 16: 335–339.
13. Butler D, Chen D, O’Dwyer K. Potent sub-MIC effect of GSK1322322 and other peptide deformylase inhibitors on in vitro growth of Staphylococcus aureus. Antimicrob Agents Chemother. 2014; 58(1): 290–296.
14. Mishra R, Chaurasia H, Singh VK. Molecular modeling, QSAR analysis and antimicrobial properties of Schiff base derivatives of isatin. J Mol Struct. 2021; 1243: 130763.
15. Chatterjee S, Ghosh R, Mandal NC. Inhibition of biofilm- and hyphal-development, two virulent features of Candida albicans by secondary metabolites of an endophytic fungus Alternaria tenuissima having broad spectrum antifungal potential. Microbiol Res. 2020; 232: 126386.
16. Kral K, Bieg T, Nawrot U. New monomeric and dimeric uridinyl derivatives as inhibitors of chitin synthase. Bioorg Chem. 2015; 61: 13–20.
17. Lipkus AH, Yuan Q, Lucas KA. Structural diversity of organic chemistry. A scaffold analysis of the CAS Registry. J Org Chem. 2008; 73: 4443–4451.
18. Katritzky AR, Ramsden CA, Scriven EFV, Taylor RJK. Introduction In: Comprehensive Heterocyclic Chemistry III. 2nd ed. Elsevier; 2008. p. 1–13.
19. Pawlowski R, Stanek F, Stodulski M. Recent advances on metal-free, visible-light-induced catalysis for assembling nitrogen- and oxygen-based heterocyclic scaffolds. Molecules. 2019; 24(22): 4201.
20. Song B, Park EY, Kim KJ, Ki SH. Repurposing of benzimidazole anthelmintic drugs as cancer therapeutics. Cancers (Basel). 2022; 14(5): 1231.
21. Hassan MM, Xu Y, Zareef M. Recent advances of nanomaterial-based optical sensor for the detection of benzimidazole fungicides in food: A review. Crit Rev Food Sci Nutr. 2023; 63(18): 2851–2872.
22. Ashfaq M, Shah SSA, Najam T. Synthetic thioamide, benzimidazole, quinolone and derivatives with carboxylic acid and ester moieties: A strategy in the design of antituberculosis agents. Curr Med Chem. 2014; 21(8): 911–931.
23. Yadav P, Shah K. Quinolines, a perpetual, multipurpose scaffold in medicinal chemistry. Bioorg Chem. 2021; 109: 104639.
24. Dhahri M, Khan FA, Emwas AH. Synthesis, DFT molecular geometry and anticancer activity of symmetrical 2,2’-(2-oxo-1H-benzo[d]imidazole-1,3(2H)-diyl) diacetate and its arylideneacetohydrazide derivatives. Materials (Basel). 2022; 15(9): 3122.
25. Hartwell LH, Kastan MB. Cell cycle control and cancer. Science. 1994; 266(5192): 1821–1828.
26. Yadav P, Shah K. An overview on synthetic and pharmaceutical prospective of pyrido[2,3-d] pyrimidines scaffold. Chem Biol Drug Des. 2021; 97(3): 633–648.
27. Li Y, Tan C, Gao C. Discovery of benzimidazole derivatives as novel multi-target EGFR, VEGFR-2 and PDGFR kinase inhibitors. Bioorg Med Chem. 2011; 19(13): 4529–4535.
28. Demirayak S, Kayagil I, Yurttas L. Microwave supported synthesis of some novel 1,3-diarylpyrazino[1,2-a]benzimidazole derivatives and investigation of their anticancer activities. Eur J Med Chem. 2011; 46(1): 411–416.
29. Sondhi SM, Rani R, Singh J. Solvent-free synthesis, anti-inflammatory and anticancer activity evaluation of tricyclic and tetracyclic benzimidazole derivatives. Bioorg Med Chem Lett. 2010; 20(7): 2306–2310.
30. Penning TD, Zhu GD, Gandhi VB. Discovery of the poly(ADP-ribose) polymerase (PARP) inhibitor 2-[(R)-2-methylpyrrolidin-2-yl]-1H-benzimidazole-4-carboxamide (ABT-888) for the treatment of cancer. J Med Chem. 2009; 52(2): 514–523.
31. Lio SC, Johnson J, Chatterjee A. Disruption of Golgi processing by 2-phenyl benzimidazole analogs blocks cell proliferation and slows tumor growth. Cancer Chemother Pharmacol. 2008; 61(6): 1045–1058.
32. Vaidya A, Pathak D, Shah K. 1,3,4-Oxadiazole and its derivatives: A review on recent progress in anticancer activities. Chem Biol Drug Des. 2021; 97(3): 572–591.
33. Agrawal OP. Organic Chemistry Reactions and Reagents. New Delhi: Goal Publishing House; 2008. p. 686.
34. Eicher T, Hauptmann S. The Chemistry of Heterocycles: Structure, Reactions, Synthesis and Applications. 2nd ed. USA: John Wiley & Sons; 2003.
35. Vita VT, Hellman S, Rosenberg SA. Cancer: Principles and Practice of Oncology. 4th ed. Philadelphia: J.B. Lippincott; 1992.
36. Hartwell LH, Kashan MB. Cell cycle control and cancer. Science. 1994; 266(5192): 1821.
37. Li Y, Tan C, Gao C, Zhang C, Luan X, Chen X, Liu H, Chen Y, Jiang Y. Discovery of benzimidazole derivatives as novel multi-target EGFR, VEGFR-2 and PDGFR kinase inhibitors. Bioorg Med Chem. 2011; 19(15): 4529–4535. doi:10.1016/j.bmc.2011.06.022.
38. Demirayak S, Kayagil I, Yurttas L. Microwave supported synthesis of some novel 1,3-diarylpyrazino[1,2-a]benzimidazole derivatives and investigation of their anticancer activities. Eur J Med Chem. 2011; 46(1): 411–416. doi:10.1016/j.ejmech.2010.11.007.
39. Sondhi SM, Rani R, Singh J, Roy P, Agrawal SK, Saxena AK. Solvent free synthesis, anti-inflammatory and anticancer activity evaluation of tricyclic and tetracyclic benzimidazole derivatives. Bioorg Med Chem Lett. 2010; 20(7): 2306–2310. doi:10.1016/j.bmcl.2010.01.147.
40. Penning TD, Zhu GD, Gandhi VB. Discovery of the poly(ADP-ribose) polymerase (PARP) inhibitor 2-[(R)-2-methylpyrrolidin-2-yl]-1H-benzimidazole-4-carboxamide (ABT-888) for the treatment of cancer. J Med Chem. 2009; 52(2): 514–523. doi:10.1021/jm801171j.
41. Lio SC, Johnson J, Chatterjee A. Disruption of Golgi processing by 2-phenyl benzimidazole analogs blocks cell proliferation and slows tumor growth. Cancer Chemother Pharmacol. 2008; 61(6): 1045–1058. doi:10.1007/s00280-007-0564-y.
42. Lee YT, Tan YJ, Oon CE. Benzimidazole and its derivatives as cancer therapeutics: the potential role from traditional to precision medicine. Acta Pharm Sin B. 2023; 13(2): 478–497.
43. Gaba M, Mohan C. Development of drugs based on imidazole and benzimidazole bioactive heterocycles: recent advances and future directions. Med Chem Res. 2016; 25(2): 173–210.
44. Grimmett MR. Imidazole and Benzimidazole Synthesis. New York: Academic Press; 1997.
45. Townsend LB, Wise DS. The synthesis and chemistry of certain anthelmintic benzimidazoles. Parasitol Today. 1990; 6(4): 107–112.
46. Jain S, Chandra V, Kumar Jain P, Pathak K, Pathak D, Vaidya A. Comprehensive review on current developments of quinoline-based anticancer agents. Arab J Chem. 2019; 12(8): 4920–4946.
47. Akkachairin B, Rodphon W, Reamtong O. Synthesis of neocryptolepines and carbocycle-fused quinolines and evaluation of their anticancer and antiplasmodial activities. Bioorg Chem. 2020; 98: 103741.
48. Ahadi H, Emami S. Modification of 7-piperazinylquinolone antibacterials to promising anticancer lead compounds: synthesis and in vitro studies. Eur J Med Chem. 2020; 187: 111960.
49. Shinde VS, Lawande PP, Sontakke VA, Khan A. Synthesis of benzimidazole nucleosides and their anticancer activity. Carbohydr Res. 2020; 498: 108159.
50. Pathak S, Sharma R. A comprehensive review on the benzimidazole scaffold as a potential nucleus for anticancer activity. Lett Org Chem. 2023; 20(10): 802–817.
51. Hue BTB, Nguyen PH, De TQ. Benzimidazole derivatives as novel Zika virus inhibitors. Chem Med Chem. 2020; 15(15): 1453–1463.
52. Sethi R, Jain S, Arora S, Saini D, Jain N. Synthesis, characterization and molecular docking studies of novel N-(benzimidazol-1-ylmethyl)-4-chlorobenzamide analogues for potential anti-inflammatory and antimicrobial activity. Anti-Inflammatory Antiallergy Agents Med Chem. 2018; 17(1): 16–31.
53. Kumar K, Awasthi D, Lee SY. Benzimidazole-based antibacterial agents against Francisella tularensis. Bioorg Med Chem. 2013; 21(10): 3318–3326.
54. Chandrika NT, Shrestha SK, Ngo HX, Garneau-Tsodikova S. Synthesis and investigation of novel benzimidazole derivatives as antifungal agents. Bioorg Med Chem. 2016; 24(15): 3680–3686.
55. Chaturvedi AK, Verma AK, Thakur JP. A novel synthesis of 2-arylbenzimidazoles in molecular sieves-MeOH system and their antitubercular activity. Bioorg Med Chem. 2018; 26(17): 4551–4559.
56. Shah DI, Sharma M, Bansal Y. Angiotensin II AT1 receptor antagonists: design, synthesis and evaluation of substituted carboxamido benzimidazole derivatives. Eur J Med Chem. 2008; 43(9): 1808–1812.
57. Kumar S, Chowdhury S, Kumar S. In silico repurposing of antipsychotic drugs for Alzheimer’s disease. BMC Neurosci. 2017; 18(1): 1–16.
58. Khan I, Tantray MA, Hamid H. Synthesis of benzimidazole based thiadiazole and carbohydrazide conjugates as glycogen synthase kinase-3β inhibitors with anti-depressant activity. Bioorg Med Chem Lett. 2016; 26(16): 4020–4024.
59. Sharma S, Hatware K, Bhadane P, Patil K. Chemistry, pharmacokinetics, pharmacodynamics and analytical methods of bilastine, a histamine H1 receptor antagonist: an update. Mini Rev Med Chem. 2021; 21(3): 3183–3190.
60. Alpan AS, Sarıkaya G, Çoban G. Mannich-benzimidazole derivatives as antioxidant and anticholinesterase inhibitors: synthesis, biological evaluations, and molecular docking study. Arch Pharm (Weinheim). 2017; 350(3): 1700399.
61. Anichina K, Argirova M, Tzoneva R. 1H-Benzimidazole-2-yl hydrazones as tubulin-targeting agents: synthesis, structural characterization, anthelmintic and antiproliferative activity against MCF-7 breast carcinoma cells, and molecular docking studies. Chem Biol Interact. 2021; 345: 109535.
62. Babkov DA, Zhukowskaya ON, Borisov AV. Towards multi-target antidiabetic agents: discovery of biphenyl-benzimidazole conjugates as AMPK activators. Bioorg Med Chem Lett. 2019; 29(18): 2443–2447.
63. Bhrigu B, Siddiqui N, Pathak D. Anticonvulsant evaluation of some newer benzimidazole derivatives: design and synthesis. Acta Pol Pharm. 2012; 69(1): 53–62.
64. Vasava MS, Bhoi MN, Rathwa SK. Benzimidazole: a milestone in the field of medicinal chemistry. Mini Rev Med Chem. 2020; 20(6): 532–565.
65. Anand K, Wakode S. Development of drugs based on benzimidazole heterocycle: recent advancement and insights. Int J Chem Stud. 2017; 5(1): 350–362.
66. Son DS, Lee ES, Adunyah SE. The antitumor potentials of benzimidazole anthelmintics as repurposing drugs. Immune Netw. 2020; 20(1): e4.
67. Debus H. Uber die Einwirkung des Ammoniaks auf Glyoxal. Justus Liebigs. Ann Chem. 1858; 107: 199–208.
68. Shaikh KA. An efficient solvent-free synthesis of imidazolines and benzimidazoles using K₄[Fe(CN)₆] catalysis. Org Commun. 2012; 5(1): 12–17.
69. Blatt AH. Organic Syntheses. Collective Volume II. New York: John Wiley & Sons. 1946; 65.
70. Wright JB. The chemistry of the benzimidazoles. Chemical Reviews. 1951; 38: 397–408.
71. Davood A, Mojgan P, Behrooz M. Acetic acid-promoted condensation of o-phenylenediamine with aldehydes into 2-aryl-1(arylmethyl)-1H-benzimidazoles under microwave irradiation. J Serb Chem Soc. 2010; 75(9): 1181–1189.
72. Rajabi F, De S, Luque R. An efficient and green synthesis of benzimidazole derivatives using SBA-15 supported catalysts. Catalysis Letters. 2015; 145.
73. Lungu L, Blaja S, Cucicova C, Ciocarlan A, Barba A, Kulcițki V, Shova S, Vornicu N, Geana EI, Mangalagiu II, Aricu A. Synthesis and Antimicrobial Activity Evaluation of Homodrimane Sesquiterpenoids with a Benzimidazole Unit. Molecules 2023; 28.
74. Diaconu D, Antoci V, Mangalagiu V, Amariucai-Mantu D, Mangalagiu, II. Quinoline–Imidazole/Benzimidazole Derivatives as Dual-/Multi-Targeting Hybrids Inhibitors with Anticancer and Antimicrobial Activity. Sci. Rep. 2022; 12: 16988.
75. Oniciuc L, Amariucai-Mantu D, Diaconu D, Mangalagiu V, Danac R, Antoci V, Mangalagiu II. Benzoquinoline Derivatives: An Attractive Approach to Newly Small Molecules with Anticancer Activity. Int. J. Mol. Sci. 2023; 24(9): 8124. https://doi.org/10.3390/ijms24098124
76. Abdel-Motaal M, Almohawes K, Tantawy MA. Antimicrobial Evaluation and Docking Study of Some New Substituted Benzimidazole-2-yl Derivatives. Bioorg. Chem. 2020; 101: 103972.
77. Shaikh IN, Hosamani KM, Kurjogi MM. Design, Synthesis, and Evaluation of New α-Aminonitrile-Based Benzimidazole Biomolecules as Potent Antimicrobial and Antitubercular Agents. Archiv der pharmazie. 2018; 351 (2).
78. Chaurasia H, Singh VK, Mishra R, Yadav AK, Ram NK, Singh P, Singh RK. Molecular Modelling, Synthesis and Antimicrobial Evaluation of Benzimidazole Nucleoside Mimetics. Bioorg. Chem. 2021; 115: 105227. https://doi.org/10.1016/j.bioorg.2021.105227
79. Abdel-Motaal M, Almohawes K, Tantawy MA. Antimicrobial Evaluation and Docking Study of Some New Substituted Benzimidazole-2-yl Derivatives. Bioorg. Chem. 2020; 101: 103972. https://doi.org/10.1016/j.bioorg.2020.103972
80. El-Gohary NS, Shaaban MI. Synthesis, Antimicrobial, Antiquorum-Sensing and Antitumor Activities of New Benzimidazole Analogs. Eur. J. Med. Chem. 2017; 137: 439–449. https://doi.org/10.1016/j.ejmech. 2017.05.064
81. Ranjith P, Rajeesh P, Haridas KR, Susanta NK. Design and Synthesis of Positional Isomers of 5- and 6-Bromo-1-[(Phenyl)sulfonyl]-2-[(4-nitrophenoxy)methyl]-1H-benzimidazoles as Possible Antimicrobial and Antitubercular Agents. Bioorg. Med. Chem. Lett. 2013; 23(18): 5228–5234. https://doi.org/10.1016/j.bmcl.2013.06.072
82. Francesconi V, Cichero E, Schenone S, Naesens L, Tonelli M. Synthesis and Biological Evaluation of Novel (Thio)semicarbazone-Based Benzimidazoles as Antiviral Agents Against Human Respiratory Viruses. Molecules. 2020; 25(7): 1487.
83. Youssif BG, Mohamed YA, Salim MT, Inagaki F, Mukai C, Abdu-Allah HH. Synthesis of Some Benzimidazole Derivatives Endowed with 1,2,3-Triazole as Potential Inhibitors of Hepatitis C Virus. Acta Pharmaceutica. 2016; 66(2): 219–231.
84. Hue BTB, Nguyen PH, De TQ, Van Hieu M, Jo E, Van TuanN, Thoa TT, Anh LD, Son NH, La Duc, Thanh D, Dupont-Rouzeyrol M, Grailhe R, Windisch MP. Benzimidazole Derivatives as Novel Zika Virus Inhibitors. Chem MedChem. 2020; 15: 1453–1463.
85. Devine SM, Challis MP, Kigotho JK, Siddiqui G, De Paoli A, MacRaild CA, Avery VM, Creek DJ, Norton RS, Scammells PJ. Discovery and Development of 2-Aminobenzimidazoles as Potent Antimalarials. Eur. J. Med. Chem. 2021; 221.
86. Okombo J, Brunschwig C, Singh K, Dziwornu GA, Barnard L, Njoroge M, Wittlin S, Chibale K. Antimalarial Pyrido[1,2-a]benzimidazole Derivatives with Mannich Base Side Chains: Synthesis, Pharmacological Evaluation, and Reactive Metabolite Trapping Studies. ACS Infect. Dis. 2019; 5: 372–384.
87. Sharma K, Shrivastava A, Mehra RN, Deora GS, Alam MM, Zaman MS, Akhter M. Synthesis of Novel Benzimidazole Acrylonitriles for Inhibition of Plasmodium falciparum Growth by Dual Target Inhibition. Arch. Pharm. (Weinheim) 2018; 351.
88. Gong Y, Karakaya SS, Guo X, Zheng P, Gold B, Ma Y. Benzimidazole-Based Compounds Kill Mycobacterium tuberculosis. Eur. J. Med. Chem 75: 336–353.
89. Haranahalli K, Tong S, Kim S, Awwa M, Chen L, Knudson SE. Structure-Activity Relationship Studies on 2,5,6-Trisubstituted Benzimidazoles Targeting Mtb-FtsZ as Antitubercular Agents. RSC Med. Chem. 2020; 12(1): 78–94.
90. Malasala S, Md Ahmad NY, Gour J, Shukla M, Kaul G, Akhir A, Gatadi S. Synthesis, Biological Evaluation and Molecular Modelling Insights of 2-Arylquinazoline Benzamide Derivatives as Anti-Tubercular Agents. J. Mol. Struct. 2020; 1218: 128493.
91. Sirim MM, Krishna VS, Sriram D, Tan OU. Novel Benzimidazole-Acrylonitrile Hybrids and Their Derivatives: Design, Synthesis and Antimycobacterial Activity. Eur J Med Chem. 2020; 188: 112010.
92. Othman D IA, Hamdi A, Tawfik SS, Elgazar AA, Mostafa AS. Identification of New Benzimidazole-Triazole Hybrids as Anticancer Agents: Multi-Target Recognition, In Vitro and In Silico Studies. J. Enzyme Inhib. Med. Chem. 2023; 38(1): 2166037.
93. Rasal NK, Sonawane RB, Jagtap SV, Potential 2,4-Dimethyl-1H-Pyrrole-3-Carboxamide Bearing Benzimidazole Template: Design, Synthesis, In Vitro Anticancer and In Silico ADME Study. Bioorg. Chem. 2020; 97: 103660.
94. Atmaca H, Ilhan S, Batır MB, Pulat CC, Guner A, Bektaş H. Novel Benzimidazole Derivatives: Synthesis, In Vitro Cytotoxicity, Apoptosis and Cell Cycle Studies. Chem. Biol. Interact. 2020; 327: 109-163.
95. Akhtar MJ, Khan AA, Ali Z, Dewangan RP, Rafi M, Hassan MQ. Synthesis of Stable Benzimidazole Derivatives Bearing Pyrazole as Anticancer and EGFR Receptor Inhibitors. Bioorg. Chem. 2018; 78: 158–169.
96. Ibrahim HA, Awadallah FM, Refaat HM, Amin KM, Molecular Docking Simulation, Synthesis and 3D Pharmacophore Studies of Novel 2-Substituted-5-Nitro-Benzimidazole Derivatives as Anticancer Agents Targeting VEGFR-2 and c-Met. Bioorg. Chem. 2018; 77: 457–470.
97. Mantu D, Antoci V, Moldoveanu C, Zbancioc G, Mangalagiu I I. Hybrid Imidazole (Benzimidazole)/Pyridine (Quinoline) Derivatives and Evaluation of Their Anticancer and Antimycobacterial Activity. J. Enzyme Inhib. Med. Chem. 2016; 31(sup2): 96–103.
98. Blaszczak-swiątkiewicz K, Mikiciuk-Olasik E. Some Characteristics of Activity of Potential Chemotherapeutics – Benzimidazole Derivatives. Adv. Med. Sci. 2015; 60(1): 125–132.
99. Moharana AK, Dash RN, Mahanandia NC, Subudhi BB. Synthesis and Anti-Inflammatory Activity Evaluation of Some Benzimidazole Derivatives. Pharm. Chem. J. 2022; 56(8): 1070–1074.
100. Maghraby MT, Abou-Ghadir OMF, Abdel-Moty SG, Ali AY, Salem OIA. Novel Class of Benzimidazole-Thiazole Hybrids: The Privileged Scaffolds of Potent Anti-Inflammatory Activity with Dual Inhibition of Cyclooxygenase and 15-Lipoxygenase Enzymes. Bioorg. Med. Chem. 2020; 28(7): 115403.
101. Rathore A, Sudhakar R, Ahsan MJ, Ali A, Subbarao N, Jadav SS, Umar S, Yar MS. In Vivo Anti-Inflammatory Activity and Docking Study of Newly Synthesized Benzimidazole Derivatives Bearing Oxadiazole and Morpholine Rings. Bioorg. Chem. 2017; 70: 107–117.
102. Moneer AA, Mohammed KO, El-Nassan HB. Synthesis of Novel Substituted Thiourea and Benzimidazole Derivatives Containing a Pyrazolone Ring as Anti-Inflammatory Agents. Chem. Biol. Drug Des. 2016; 87(5): 784–793.
103. Wu Z, Xia MB, Bertsetseg D, Wang YH, Bao XL, Zhu WB, Xu T, Chen PR, Tang HS, Yan YJ, Chen ZL. Design, Synthesis and Biological Evaluation of Novel Fluoro-Substituted Benzimidazole Derivatives with Anti-Hypertension Activities. Bioorg. Chem. 2020; 101.
104. Wu Z, Xia MB, Bertsetseg D, Wang YH, Bao XL, Zhu WB, Tao-Xu Chen PR, Tang HS, Yan YJ, Chen ZL. Design, Synthesis and Biological Evaluation of Novel Fluoro-Substituted Benzimidazole Derivatives with Anti-Hypertension Activities. Bioorg. Chem. 2020; 101.
105. Zhang Y, Xu J, Li Y, Yao H, Wu X. Design, Synthesis, and Pharmacological Evaluation of Novel NO-Releasing Benzimidazole Hybrids as Potential Antihypertensive Candidate. Chem. Biol. Drug Des. 2015; 85: 541–548.
106. Zhu W, Da Y, Wu D, Zheng H, Zhu L, Wang L, Yan Y, Chen Z. Design, Synthesis and Biological Evaluation of New 5-Nitro Benzimidazole Derivatives as AT1 Antagonists with Anti-Hypertension Activities. Bioorg. Med. Chem. 2014; 22: 2294–2302.
107. Khan I, Tantray MA, Hamid H, Alam MS, Kalam A, Dhulap A. Synthesis of benzimidazole based thiadiazole and carbohydrazide conjugates as glycogen synthase kinase-3β inhibitors with anti-depressant activity. Bioorg Med Chem Lett. 2016 Aug 15; 26(16): 4020-4.
108. Deswal L, Verma V, Kumar D, Kaushik CP, Kumar A, Deswal Y, Punia S. Synthesis and antidiabetic evaluation of benzimidazole-tethered 1,2,3-triazoles. Arch Pharm (Weinheim). 2020 Sep; 353(9): e2000090.
109. Zawawi NK, Taha M, Ahmat N, Ismail NH, Wadood A, Rahim F. Synthesis, molecular docking studies of hybrid benzimidazole as α-glucosidase inhibitor. Bioorg Chem. 2017 Feb; 70: 184-191.
110. Aroua LM, Almuhaylan HR, Alminderej FM, Messaoudi S, Chigurupati S, Al-Mahmoud S, Mohammed HA. A facile approach synthesis of benzoylaryl benzimidazole as potential α-amylase and α-glucosidase inhibitor with antioxidant activity. Bioorg Chem. 2021 Sep; 114: 105073.
111. Jain P, Sharma PK, Rajak H, Pawar RS, Patil UK, Singour PK. Design, synthesis, and biological evaluation of some novel benzimidazole derivatives for their potential anticonvulsant activity. Arch Pharm Res. 2010 Jul; 33(7): 971-80.
112. Zhou B, Li B, Yi W, Bu X, Ma L. Synthesis, antioxidant, and antimicrobial evaluation of some 2-arylbenzimidazole derivatives. Bioorg Med Chem Lett. 2013 Jul 1; 23(13): 3759-63.
113. Matysiak J, Skrzypek A, Karpinska M, Czarnecka K, Szymanski P, Bajda M, Niewiadomy A. Biological Evaluation, Molecular Docking, and SAR Studies of Novel 2-(2,4-Dihydroxyphenyl)-1H- Benzimidazole Analogues. Biomolecules. 2019; 9.
114. Alpan AS, Sarıkaya G, Coban G, Parlar S, Armagan G, Alptuzun V. Mannich-Benzimidazole Derivatives as Antioxidant and Anticholinesterase Inhibitors: Synthesis, Biological Evaluations, and Molecular Docking Study. Arch. Pharm. (Weinheim). 2017; 350.
2. Shinde RA, Adole VA, Jagdale BS, Pawar TB. Superfast synthesis, antibacterial and antifungal studies of halo-aryl and heterocyclic tagged 2,3-dihydro-1H-inden-1-one candidates. Monatsh Chem. 2021; 152: 649–658.
3. Reddy GM, Kumari AK, Reddy VH, Garcia JR. Novel pyranopyrazole derivatives comprising a benzoxazole core as antimicrobial inhibitors: Design, synthesis, microbial resistance and machine-aided results. Bioorg Chem. 2020; 100: 103914.
4. Odusami JA, Ikhile MI, Izunobi JU. Synthesis of substituted N-(2′-nitrophenyl)pyrrolidine-2-carboxamides towards the design of proline-rich antimicrobial peptide mimics to eliminate bacterial resistance to antibiotics. Bioorg Chem. 2020; 105: 104408.
5. El Faydy M, Dahaieh N, Ounine K. Synthesis, identification, antibacterial activity, ADME/T and 1BNA-docking investigations of 8-quinolinol analogs bearing a benzimidazole moiety. Arab J Sci Eng. 2022; 47: 497–510.
6. Di Luca M, Marzo T. Development of effective antibacterial treatment: Lessons from the past and novel approaches. Antibiotics (Basel). 2021; 10(2): 230.
7. Mohanty P, Behera S, Behura R. Antibacterial activity of thiazole and its derivatives: A review. Biointerface Res Appl Chem. 2022; 12: 2171–2195.
8. Rivera JA, Larsson J, Volkov IL. Real-time measurements of aminoglycoside effects on protein synthesis in live cells. Proc Natl Acad Sci U S A. 2021; 118(2): e2013315118.
9. Almeida L, Dhillon-LaBrooy A, Castro CN. Ribosome-targeting antibiotics impair T cell effector function and ameliorate autoimmunity by blocking mitochondrial protein synthesis. Immunity. 2021; 54(1): 68–83.
10. Darwis W, Supriati R, Sipriyadi. Antibacterial potency of lichen Teloschisthes flavicans from Kepahiang district against Staphylococcus aureus and Pseudomonas aeruginosa. Proc 3rd KOBI Congr Int Natl Conf (KOBICINC 2020). 2021; 14: 547–552.
11. Wei MP, Yu H, Guo YH. Synergistic antibacterial combination of sapindoside A and B changes the fatty acid compositions and membrane properties of Cutibacterium acnes. Microbiol Res. 2021; 255: 126888.
12. Sonousi A, Quirke JCK, Waduge P. An advanced apralog with increased in vitro and in vivo activity toward gram-negative pathogens and reduced ex vivo cochleotoxicity. ChemMedChem. 2021; 16: 335–339.
13. Butler D, Chen D, O’Dwyer K. Potent sub-MIC effect of GSK1322322 and other peptide deformylase inhibitors on in vitro growth of Staphylococcus aureus. Antimicrob Agents Chemother. 2014; 58(1): 290–296.
14. Mishra R, Chaurasia H, Singh VK. Molecular modeling, QSAR analysis and antimicrobial properties of Schiff base derivatives of isatin. J Mol Struct. 2021; 1243: 130763.
15. Chatterjee S, Ghosh R, Mandal NC. Inhibition of biofilm- and hyphal-development, two virulent features of Candida albicans by secondary metabolites of an endophytic fungus Alternaria tenuissima having broad spectrum antifungal potential. Microbiol Res. 2020; 232: 126386.
16. Kral K, Bieg T, Nawrot U. New monomeric and dimeric uridinyl derivatives as inhibitors of chitin synthase. Bioorg Chem. 2015; 61: 13–20.
17. Lipkus AH, Yuan Q, Lucas KA. Structural diversity of organic chemistry. A scaffold analysis of the CAS Registry. J Org Chem. 2008; 73: 4443–4451.
18. Katritzky AR, Ramsden CA, Scriven EFV, Taylor RJK. Introduction In: Comprehensive Heterocyclic Chemistry III. 2nd ed. Elsevier; 2008. p. 1–13.
19. Pawlowski R, Stanek F, Stodulski M. Recent advances on metal-free, visible-light-induced catalysis for assembling nitrogen- and oxygen-based heterocyclic scaffolds. Molecules. 2019; 24(22): 4201.
20. Song B, Park EY, Kim KJ, Ki SH. Repurposing of benzimidazole anthelmintic drugs as cancer therapeutics. Cancers (Basel). 2022; 14(5): 1231.
21. Hassan MM, Xu Y, Zareef M. Recent advances of nanomaterial-based optical sensor for the detection of benzimidazole fungicides in food: A review. Crit Rev Food Sci Nutr. 2023; 63(18): 2851–2872.
22. Ashfaq M, Shah SSA, Najam T. Synthetic thioamide, benzimidazole, quinolone and derivatives with carboxylic acid and ester moieties: A strategy in the design of antituberculosis agents. Curr Med Chem. 2014; 21(8): 911–931.
23. Yadav P, Shah K. Quinolines, a perpetual, multipurpose scaffold in medicinal chemistry. Bioorg Chem. 2021; 109: 104639.
24. Dhahri M, Khan FA, Emwas AH. Synthesis, DFT molecular geometry and anticancer activity of symmetrical 2,2’-(2-oxo-1H-benzo[d]imidazole-1,3(2H)-diyl) diacetate and its arylideneacetohydrazide derivatives. Materials (Basel). 2022; 15(9): 3122.
25. Hartwell LH, Kastan MB. Cell cycle control and cancer. Science. 1994; 266(5192): 1821–1828.
26. Yadav P, Shah K. An overview on synthetic and pharmaceutical prospective of pyrido[2,3-d] pyrimidines scaffold. Chem Biol Drug Des. 2021; 97(3): 633–648.
27. Li Y, Tan C, Gao C. Discovery of benzimidazole derivatives as novel multi-target EGFR, VEGFR-2 and PDGFR kinase inhibitors. Bioorg Med Chem. 2011; 19(13): 4529–4535.
28. Demirayak S, Kayagil I, Yurttas L. Microwave supported synthesis of some novel 1,3-diarylpyrazino[1,2-a]benzimidazole derivatives and investigation of their anticancer activities. Eur J Med Chem. 2011; 46(1): 411–416.
29. Sondhi SM, Rani R, Singh J. Solvent-free synthesis, anti-inflammatory and anticancer activity evaluation of tricyclic and tetracyclic benzimidazole derivatives. Bioorg Med Chem Lett. 2010; 20(7): 2306–2310.
30. Penning TD, Zhu GD, Gandhi VB. Discovery of the poly(ADP-ribose) polymerase (PARP) inhibitor 2-[(R)-2-methylpyrrolidin-2-yl]-1H-benzimidazole-4-carboxamide (ABT-888) for the treatment of cancer. J Med Chem. 2009; 52(2): 514–523.
31. Lio SC, Johnson J, Chatterjee A. Disruption of Golgi processing by 2-phenyl benzimidazole analogs blocks cell proliferation and slows tumor growth. Cancer Chemother Pharmacol. 2008; 61(6): 1045–1058.
32. Vaidya A, Pathak D, Shah K. 1,3,4-Oxadiazole and its derivatives: A review on recent progress in anticancer activities. Chem Biol Drug Des. 2021; 97(3): 572–591.
33. Agrawal OP. Organic Chemistry Reactions and Reagents. New Delhi: Goal Publishing House; 2008. p. 686.
34. Eicher T, Hauptmann S. The Chemistry of Heterocycles: Structure, Reactions, Synthesis and Applications. 2nd ed. USA: John Wiley & Sons; 2003.
35. Vita VT, Hellman S, Rosenberg SA. Cancer: Principles and Practice of Oncology. 4th ed. Philadelphia: J.B. Lippincott; 1992.
36. Hartwell LH, Kashan MB. Cell cycle control and cancer. Science. 1994; 266(5192): 1821.
37. Li Y, Tan C, Gao C, Zhang C, Luan X, Chen X, Liu H, Chen Y, Jiang Y. Discovery of benzimidazole derivatives as novel multi-target EGFR, VEGFR-2 and PDGFR kinase inhibitors. Bioorg Med Chem. 2011; 19(15): 4529–4535. doi:10.1016/j.bmc.2011.06.022.
38. Demirayak S, Kayagil I, Yurttas L. Microwave supported synthesis of some novel 1,3-diarylpyrazino[1,2-a]benzimidazole derivatives and investigation of their anticancer activities. Eur J Med Chem. 2011; 46(1): 411–416. doi:10.1016/j.ejmech.2010.11.007.
39. Sondhi SM, Rani R, Singh J, Roy P, Agrawal SK, Saxena AK. Solvent free synthesis, anti-inflammatory and anticancer activity evaluation of tricyclic and tetracyclic benzimidazole derivatives. Bioorg Med Chem Lett. 2010; 20(7): 2306–2310. doi:10.1016/j.bmcl.2010.01.147.
40. Penning TD, Zhu GD, Gandhi VB. Discovery of the poly(ADP-ribose) polymerase (PARP) inhibitor 2-[(R)-2-methylpyrrolidin-2-yl]-1H-benzimidazole-4-carboxamide (ABT-888) for the treatment of cancer. J Med Chem. 2009; 52(2): 514–523. doi:10.1021/jm801171j.
41. Lio SC, Johnson J, Chatterjee A. Disruption of Golgi processing by 2-phenyl benzimidazole analogs blocks cell proliferation and slows tumor growth. Cancer Chemother Pharmacol. 2008; 61(6): 1045–1058. doi:10.1007/s00280-007-0564-y.
42. Lee YT, Tan YJ, Oon CE. Benzimidazole and its derivatives as cancer therapeutics: the potential role from traditional to precision medicine. Acta Pharm Sin B. 2023; 13(2): 478–497.
43. Gaba M, Mohan C. Development of drugs based on imidazole and benzimidazole bioactive heterocycles: recent advances and future directions. Med Chem Res. 2016; 25(2): 173–210.
44. Grimmett MR. Imidazole and Benzimidazole Synthesis. New York: Academic Press; 1997.
45. Townsend LB, Wise DS. The synthesis and chemistry of certain anthelmintic benzimidazoles. Parasitol Today. 1990; 6(4): 107–112.
46. Jain S, Chandra V, Kumar Jain P, Pathak K, Pathak D, Vaidya A. Comprehensive review on current developments of quinoline-based anticancer agents. Arab J Chem. 2019; 12(8): 4920–4946.
47. Akkachairin B, Rodphon W, Reamtong O. Synthesis of neocryptolepines and carbocycle-fused quinolines and evaluation of their anticancer and antiplasmodial activities. Bioorg Chem. 2020; 98: 103741.
48. Ahadi H, Emami S. Modification of 7-piperazinylquinolone antibacterials to promising anticancer lead compounds: synthesis and in vitro studies. Eur J Med Chem. 2020; 187: 111960.
49. Shinde VS, Lawande PP, Sontakke VA, Khan A. Synthesis of benzimidazole nucleosides and their anticancer activity. Carbohydr Res. 2020; 498: 108159.
50. Pathak S, Sharma R. A comprehensive review on the benzimidazole scaffold as a potential nucleus for anticancer activity. Lett Org Chem. 2023; 20(10): 802–817.
51. Hue BTB, Nguyen PH, De TQ. Benzimidazole derivatives as novel Zika virus inhibitors. Chem Med Chem. 2020; 15(15): 1453–1463.
52. Sethi R, Jain S, Arora S, Saini D, Jain N. Synthesis, characterization and molecular docking studies of novel N-(benzimidazol-1-ylmethyl)-4-chlorobenzamide analogues for potential anti-inflammatory and antimicrobial activity. Anti-Inflammatory Antiallergy Agents Med Chem. 2018; 17(1): 16–31.
53. Kumar K, Awasthi D, Lee SY. Benzimidazole-based antibacterial agents against Francisella tularensis. Bioorg Med Chem. 2013; 21(10): 3318–3326.
54. Chandrika NT, Shrestha SK, Ngo HX, Garneau-Tsodikova S. Synthesis and investigation of novel benzimidazole derivatives as antifungal agents. Bioorg Med Chem. 2016; 24(15): 3680–3686.
55. Chaturvedi AK, Verma AK, Thakur JP. A novel synthesis of 2-arylbenzimidazoles in molecular sieves-MeOH system and their antitubercular activity. Bioorg Med Chem. 2018; 26(17): 4551–4559.
56. Shah DI, Sharma M, Bansal Y. Angiotensin II AT1 receptor antagonists: design, synthesis and evaluation of substituted carboxamido benzimidazole derivatives. Eur J Med Chem. 2008; 43(9): 1808–1812.
57. Kumar S, Chowdhury S, Kumar S. In silico repurposing of antipsychotic drugs for Alzheimer’s disease. BMC Neurosci. 2017; 18(1): 1–16.
58. Khan I, Tantray MA, Hamid H. Synthesis of benzimidazole based thiadiazole and carbohydrazide conjugates as glycogen synthase kinase-3β inhibitors with anti-depressant activity. Bioorg Med Chem Lett. 2016; 26(16): 4020–4024.
59. Sharma S, Hatware K, Bhadane P, Patil K. Chemistry, pharmacokinetics, pharmacodynamics and analytical methods of bilastine, a histamine H1 receptor antagonist: an update. Mini Rev Med Chem. 2021; 21(3): 3183–3190.
60. Alpan AS, Sarıkaya G, Çoban G. Mannich-benzimidazole derivatives as antioxidant and anticholinesterase inhibitors: synthesis, biological evaluations, and molecular docking study. Arch Pharm (Weinheim). 2017; 350(3): 1700399.
61. Anichina K, Argirova M, Tzoneva R. 1H-Benzimidazole-2-yl hydrazones as tubulin-targeting agents: synthesis, structural characterization, anthelmintic and antiproliferative activity against MCF-7 breast carcinoma cells, and molecular docking studies. Chem Biol Interact. 2021; 345: 109535.
62. Babkov DA, Zhukowskaya ON, Borisov AV. Towards multi-target antidiabetic agents: discovery of biphenyl-benzimidazole conjugates as AMPK activators. Bioorg Med Chem Lett. 2019; 29(18): 2443–2447.
63. Bhrigu B, Siddiqui N, Pathak D. Anticonvulsant evaluation of some newer benzimidazole derivatives: design and synthesis. Acta Pol Pharm. 2012; 69(1): 53–62.
64. Vasava MS, Bhoi MN, Rathwa SK. Benzimidazole: a milestone in the field of medicinal chemistry. Mini Rev Med Chem. 2020; 20(6): 532–565.
65. Anand K, Wakode S. Development of drugs based on benzimidazole heterocycle: recent advancement and insights. Int J Chem Stud. 2017; 5(1): 350–362.
66. Son DS, Lee ES, Adunyah SE. The antitumor potentials of benzimidazole anthelmintics as repurposing drugs. Immune Netw. 2020; 20(1): e4.
67. Debus H. Uber die Einwirkung des Ammoniaks auf Glyoxal. Justus Liebigs. Ann Chem. 1858; 107: 199–208.
68. Shaikh KA. An efficient solvent-free synthesis of imidazolines and benzimidazoles using K₄[Fe(CN)₆] catalysis. Org Commun. 2012; 5(1): 12–17.
69. Blatt AH. Organic Syntheses. Collective Volume II. New York: John Wiley & Sons. 1946; 65.
70. Wright JB. The chemistry of the benzimidazoles. Chemical Reviews. 1951; 38: 397–408.
71. Davood A, Mojgan P, Behrooz M. Acetic acid-promoted condensation of o-phenylenediamine with aldehydes into 2-aryl-1(arylmethyl)-1H-benzimidazoles under microwave irradiation. J Serb Chem Soc. 2010; 75(9): 1181–1189.
72. Rajabi F, De S, Luque R. An efficient and green synthesis of benzimidazole derivatives using SBA-15 supported catalysts. Catalysis Letters. 2015; 145.
73. Lungu L, Blaja S, Cucicova C, Ciocarlan A, Barba A, Kulcițki V, Shova S, Vornicu N, Geana EI, Mangalagiu II, Aricu A. Synthesis and Antimicrobial Activity Evaluation of Homodrimane Sesquiterpenoids with a Benzimidazole Unit. Molecules 2023; 28.
74. Diaconu D, Antoci V, Mangalagiu V, Amariucai-Mantu D, Mangalagiu, II. Quinoline–Imidazole/Benzimidazole Derivatives as Dual-/Multi-Targeting Hybrids Inhibitors with Anticancer and Antimicrobial Activity. Sci. Rep. 2022; 12: 16988.
75. Oniciuc L, Amariucai-Mantu D, Diaconu D, Mangalagiu V, Danac R, Antoci V, Mangalagiu II. Benzoquinoline Derivatives: An Attractive Approach to Newly Small Molecules with Anticancer Activity. Int. J. Mol. Sci. 2023; 24(9): 8124. https://doi.org/10.3390/ijms24098124
76. Abdel-Motaal M, Almohawes K, Tantawy MA. Antimicrobial Evaluation and Docking Study of Some New Substituted Benzimidazole-2-yl Derivatives. Bioorg. Chem. 2020; 101: 103972.
77. Shaikh IN, Hosamani KM, Kurjogi MM. Design, Synthesis, and Evaluation of New α-Aminonitrile-Based Benzimidazole Biomolecules as Potent Antimicrobial and Antitubercular Agents. Archiv der pharmazie. 2018; 351 (2).
78. Chaurasia H, Singh VK, Mishra R, Yadav AK, Ram NK, Singh P, Singh RK. Molecular Modelling, Synthesis and Antimicrobial Evaluation of Benzimidazole Nucleoside Mimetics. Bioorg. Chem. 2021; 115: 105227. https://doi.org/10.1016/j.bioorg.2021.105227
79. Abdel-Motaal M, Almohawes K, Tantawy MA. Antimicrobial Evaluation and Docking Study of Some New Substituted Benzimidazole-2-yl Derivatives. Bioorg. Chem. 2020; 101: 103972. https://doi.org/10.1016/j.bioorg.2020.103972
80. El-Gohary NS, Shaaban MI. Synthesis, Antimicrobial, Antiquorum-Sensing and Antitumor Activities of New Benzimidazole Analogs. Eur. J. Med. Chem. 2017; 137: 439–449. https://doi.org/10.1016/j.ejmech. 2017.05.064
81. Ranjith P, Rajeesh P, Haridas KR, Susanta NK. Design and Synthesis of Positional Isomers of 5- and 6-Bromo-1-[(Phenyl)sulfonyl]-2-[(4-nitrophenoxy)methyl]-1H-benzimidazoles as Possible Antimicrobial and Antitubercular Agents. Bioorg. Med. Chem. Lett. 2013; 23(18): 5228–5234. https://doi.org/10.1016/j.bmcl.2013.06.072
82. Francesconi V, Cichero E, Schenone S, Naesens L, Tonelli M. Synthesis and Biological Evaluation of Novel (Thio)semicarbazone-Based Benzimidazoles as Antiviral Agents Against Human Respiratory Viruses. Molecules. 2020; 25(7): 1487.
83. Youssif BG, Mohamed YA, Salim MT, Inagaki F, Mukai C, Abdu-Allah HH. Synthesis of Some Benzimidazole Derivatives Endowed with 1,2,3-Triazole as Potential Inhibitors of Hepatitis C Virus. Acta Pharmaceutica. 2016; 66(2): 219–231.
84. Hue BTB, Nguyen PH, De TQ, Van Hieu M, Jo E, Van TuanN, Thoa TT, Anh LD, Son NH, La Duc, Thanh D, Dupont-Rouzeyrol M, Grailhe R, Windisch MP. Benzimidazole Derivatives as Novel Zika Virus Inhibitors. Chem MedChem. 2020; 15: 1453–1463.
85. Devine SM, Challis MP, Kigotho JK, Siddiqui G, De Paoli A, MacRaild CA, Avery VM, Creek DJ, Norton RS, Scammells PJ. Discovery and Development of 2-Aminobenzimidazoles as Potent Antimalarials. Eur. J. Med. Chem. 2021; 221.
86. Okombo J, Brunschwig C, Singh K, Dziwornu GA, Barnard L, Njoroge M, Wittlin S, Chibale K. Antimalarial Pyrido[1,2-a]benzimidazole Derivatives with Mannich Base Side Chains: Synthesis, Pharmacological Evaluation, and Reactive Metabolite Trapping Studies. ACS Infect. Dis. 2019; 5: 372–384.
87. Sharma K, Shrivastava A, Mehra RN, Deora GS, Alam MM, Zaman MS, Akhter M. Synthesis of Novel Benzimidazole Acrylonitriles for Inhibition of Plasmodium falciparum Growth by Dual Target Inhibition. Arch. Pharm. (Weinheim) 2018; 351.
88. Gong Y, Karakaya SS, Guo X, Zheng P, Gold B, Ma Y. Benzimidazole-Based Compounds Kill Mycobacterium tuberculosis. Eur. J. Med. Chem 75: 336–353.
89. Haranahalli K, Tong S, Kim S, Awwa M, Chen L, Knudson SE. Structure-Activity Relationship Studies on 2,5,6-Trisubstituted Benzimidazoles Targeting Mtb-FtsZ as Antitubercular Agents. RSC Med. Chem. 2020; 12(1): 78–94.
90. Malasala S, Md Ahmad NY, Gour J, Shukla M, Kaul G, Akhir A, Gatadi S. Synthesis, Biological Evaluation and Molecular Modelling Insights of 2-Arylquinazoline Benzamide Derivatives as Anti-Tubercular Agents. J. Mol. Struct. 2020; 1218: 128493.
91. Sirim MM, Krishna VS, Sriram D, Tan OU. Novel Benzimidazole-Acrylonitrile Hybrids and Their Derivatives: Design, Synthesis and Antimycobacterial Activity. Eur J Med Chem. 2020; 188: 112010.
92. Othman D IA, Hamdi A, Tawfik SS, Elgazar AA, Mostafa AS. Identification of New Benzimidazole-Triazole Hybrids as Anticancer Agents: Multi-Target Recognition, In Vitro and In Silico Studies. J. Enzyme Inhib. Med. Chem. 2023; 38(1): 2166037.
93. Rasal NK, Sonawane RB, Jagtap SV, Potential 2,4-Dimethyl-1H-Pyrrole-3-Carboxamide Bearing Benzimidazole Template: Design, Synthesis, In Vitro Anticancer and In Silico ADME Study. Bioorg. Chem. 2020; 97: 103660.
94. Atmaca H, Ilhan S, Batır MB, Pulat CC, Guner A, Bektaş H. Novel Benzimidazole Derivatives: Synthesis, In Vitro Cytotoxicity, Apoptosis and Cell Cycle Studies. Chem. Biol. Interact. 2020; 327: 109-163.
95. Akhtar MJ, Khan AA, Ali Z, Dewangan RP, Rafi M, Hassan MQ. Synthesis of Stable Benzimidazole Derivatives Bearing Pyrazole as Anticancer and EGFR Receptor Inhibitors. Bioorg. Chem. 2018; 78: 158–169.
96. Ibrahim HA, Awadallah FM, Refaat HM, Amin KM, Molecular Docking Simulation, Synthesis and 3D Pharmacophore Studies of Novel 2-Substituted-5-Nitro-Benzimidazole Derivatives as Anticancer Agents Targeting VEGFR-2 and c-Met. Bioorg. Chem. 2018; 77: 457–470.
97. Mantu D, Antoci V, Moldoveanu C, Zbancioc G, Mangalagiu I I. Hybrid Imidazole (Benzimidazole)/Pyridine (Quinoline) Derivatives and Evaluation of Their Anticancer and Antimycobacterial Activity. J. Enzyme Inhib. Med. Chem. 2016; 31(sup2): 96–103.
98. Blaszczak-swiątkiewicz K, Mikiciuk-Olasik E. Some Characteristics of Activity of Potential Chemotherapeutics – Benzimidazole Derivatives. Adv. Med. Sci. 2015; 60(1): 125–132.
99. Moharana AK, Dash RN, Mahanandia NC, Subudhi BB. Synthesis and Anti-Inflammatory Activity Evaluation of Some Benzimidazole Derivatives. Pharm. Chem. J. 2022; 56(8): 1070–1074.
100. Maghraby MT, Abou-Ghadir OMF, Abdel-Moty SG, Ali AY, Salem OIA. Novel Class of Benzimidazole-Thiazole Hybrids: The Privileged Scaffolds of Potent Anti-Inflammatory Activity with Dual Inhibition of Cyclooxygenase and 15-Lipoxygenase Enzymes. Bioorg. Med. Chem. 2020; 28(7): 115403.
101. Rathore A, Sudhakar R, Ahsan MJ, Ali A, Subbarao N, Jadav SS, Umar S, Yar MS. In Vivo Anti-Inflammatory Activity and Docking Study of Newly Synthesized Benzimidazole Derivatives Bearing Oxadiazole and Morpholine Rings. Bioorg. Chem. 2017; 70: 107–117.
102. Moneer AA, Mohammed KO, El-Nassan HB. Synthesis of Novel Substituted Thiourea and Benzimidazole Derivatives Containing a Pyrazolone Ring as Anti-Inflammatory Agents. Chem. Biol. Drug Des. 2016; 87(5): 784–793.
103. Wu Z, Xia MB, Bertsetseg D, Wang YH, Bao XL, Zhu WB, Xu T, Chen PR, Tang HS, Yan YJ, Chen ZL. Design, Synthesis and Biological Evaluation of Novel Fluoro-Substituted Benzimidazole Derivatives with Anti-Hypertension Activities. Bioorg. Chem. 2020; 101.
104. Wu Z, Xia MB, Bertsetseg D, Wang YH, Bao XL, Zhu WB, Tao-Xu Chen PR, Tang HS, Yan YJ, Chen ZL. Design, Synthesis and Biological Evaluation of Novel Fluoro-Substituted Benzimidazole Derivatives with Anti-Hypertension Activities. Bioorg. Chem. 2020; 101.
105. Zhang Y, Xu J, Li Y, Yao H, Wu X. Design, Synthesis, and Pharmacological Evaluation of Novel NO-Releasing Benzimidazole Hybrids as Potential Antihypertensive Candidate. Chem. Biol. Drug Des. 2015; 85: 541–548.
106. Zhu W, Da Y, Wu D, Zheng H, Zhu L, Wang L, Yan Y, Chen Z. Design, Synthesis and Biological Evaluation of New 5-Nitro Benzimidazole Derivatives as AT1 Antagonists with Anti-Hypertension Activities. Bioorg. Med. Chem. 2014; 22: 2294–2302.
107. Khan I, Tantray MA, Hamid H, Alam MS, Kalam A, Dhulap A. Synthesis of benzimidazole based thiadiazole and carbohydrazide conjugates as glycogen synthase kinase-3β inhibitors with anti-depressant activity. Bioorg Med Chem Lett. 2016 Aug 15; 26(16): 4020-4.
108. Deswal L, Verma V, Kumar D, Kaushik CP, Kumar A, Deswal Y, Punia S. Synthesis and antidiabetic evaluation of benzimidazole-tethered 1,2,3-triazoles. Arch Pharm (Weinheim). 2020 Sep; 353(9): e2000090.
109. Zawawi NK, Taha M, Ahmat N, Ismail NH, Wadood A, Rahim F. Synthesis, molecular docking studies of hybrid benzimidazole as α-glucosidase inhibitor. Bioorg Chem. 2017 Feb; 70: 184-191.
110. Aroua LM, Almuhaylan HR, Alminderej FM, Messaoudi S, Chigurupati S, Al-Mahmoud S, Mohammed HA. A facile approach synthesis of benzoylaryl benzimidazole as potential α-amylase and α-glucosidase inhibitor with antioxidant activity. Bioorg Chem. 2021 Sep; 114: 105073.
111. Jain P, Sharma PK, Rajak H, Pawar RS, Patil UK, Singour PK. Design, synthesis, and biological evaluation of some novel benzimidazole derivatives for their potential anticonvulsant activity. Arch Pharm Res. 2010 Jul; 33(7): 971-80.
112. Zhou B, Li B, Yi W, Bu X, Ma L. Synthesis, antioxidant, and antimicrobial evaluation of some 2-arylbenzimidazole derivatives. Bioorg Med Chem Lett. 2013 Jul 1; 23(13): 3759-63.
113. Matysiak J, Skrzypek A, Karpinska M, Czarnecka K, Szymanski P, Bajda M, Niewiadomy A. Biological Evaluation, Molecular Docking, and SAR Studies of Novel 2-(2,4-Dihydroxyphenyl)-1H- Benzimidazole Analogues. Biomolecules. 2019; 9.
114. Alpan AS, Sarıkaya G, Coban G, Parlar S, Armagan G, Alptuzun V. Mannich-Benzimidazole Derivatives as Antioxidant and Anticholinesterase Inhibitors: Synthesis, Biological Evaluations, and Molecular Docking Study. Arch. Pharm. (Weinheim). 2017; 350.
Statistics
123 Views | 82 Downloads
How to Cite
Chander Shekhar Sharma, Mukesh Kumar Gupta, and Shikha Sharma. “BENZIMIDAZOLE SCAFFOLD: A PRIVILEGED CORE FOR DIVERSE PHARMACOLOGICAL ACTIVITIES”. Current Research in Pharmaceutical Sciences, Vol. 15, no. 3, Oct. 2025, pp. 83-104, doi:10.24092/CRPS.2025.150302.
Section
Review Articles
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
.